53 year old male with CKD on HD, known extensive inoperable severe calcific CAD and s/p SAVR in Nov 2017, now presented with NSTEMI and TnI 8.5. A Cardiac Cath on October 30, 2018 revealed severe calcific 3 V CAD: new totally occluded calcified prox LCx, known CTO of D1 & Ramus and multiple 80-90% lesions of mid, distal RCA and RPDA with SYNTAX score of 53 and LVEF 45%. Patient underwent successful intervention of culprit calcified proximal LCx using Rotational Atherectomy and DES (5/18mm Resolute Onyx). Patient did well and continued to mild angina and dyspnea. Patient is now planned for staged PCI of severely calcified RCA lesions using Rotational Atherectomy (step burs) and multiple drug eluting stents.
Moderator: Sameer Mehta, MD
Yes. Orbital atherectomy (OA) could have also been used but final results may not have been this excellent because large RCA vessel size (4mm); 1.25mm OA crown, can give lumen of 1.6-1.7mm only. Laser atherectomy will be less effective in this heavily calcified lesion in large vessel.
This kind of severe calcification usually will not yield with high pressure non-compliant balloon dilatation or atherotomy by cutting balloon or Angiosculpt.
In about 5% of the total Rota cases. Most common are 1.5mm and 1.75mm; both around 40% each. We use 1.25mm burr in 10-12% of Rota cases.
Since this pt is in Afib, our recommended strategy is Clopidogrel 75mg daily for lifelong with Warfarin daily to keep INR around 2 lifelong for Afib. If needed, we can switch clopidogrel to aspirin 81mg after one year. We do it advocate triple therapy post DES. Our usual DAPT strategy in pts requiring AC is Xarelto 15mg daily and plavix 75mg daily. This pt could not get approval for NOAC from the insurance and hence is on warfarin.
The advent of RotaPro device has made the equipment simpler now.
Drawback of RotaPro are; big harness cable, separate activation knobs for burring and for Dynaglide, lack of tactile feedback as burr seems to advance with little resistance.
Actually, overall atherectomy use at MSH has gone up from 16-17% in 2013 to 24-25% today; 75% RA and 25% OA.
We do not have any approved commercially available anti-inflammatory agent, and in the current available agents, high dose statins with added Ezetimibe or a PCSK9 inhibitor still remain the best (only) agent for RIR.
High dose statins are very important to suppress vascular inflammation.
NIR is a great device to identify TCFA and lipid contents of the plaque. It’s utility remains in the research arena. NIR is making a comeback in USA with a new reformed catheter with a Japanese sponsor. It still needs to be seen, where it’s actual role will be in the future.
71 year old male with multiple CAD risk factors presented with NSTEMI, pneumonia and septic shock in October 2018.
57 year old diabetic male presented with new onset CCS Class II angina and positive stress echo for multisegmental wall hypokinesis.
86 year old female with chronic stable angina CCS Class II and positive MPI for two years being managed on medication.
62 year old male presented with CCS Class II angina and positive SPECT MPI for basal inferior and inferolateral moderate size area of ischemia and infarction.